Compare Illumina, Inc. (ILMN) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs iShares Russell 2000 ETF — how do they compare? Illumina, Inc. trades at $266.42 (market cap $39.95B), while iShares Russell 2000 ETF trades at $278.71 (market cap $77.70B). The key difference: iShares Russell 2000 ETF is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, iShares Russell 2000 ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and iShares Russell 2000 ETF for 83 Days on average.
| ILMN | IWM | |
|---|---|---|
Market Cap | $39.95B | $77.70B |
Volume | 3,169,503 | 35,598,983 |
Sector | Health | — |
52-Week High | $293.69 | $305.06 |
52-Week Low | $91.00 | $229.13 |
Typical Hold Time | 83 Days | 83 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
IWM trades at $278.05, up 0.12% with bearish technical signals from moving averages. The small-cap ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices. Recent news highlights IWM's decade-long trailing of the S&P 500 while carrying higher risk, with institutional selling pressure evident from Envestnet's 4.6% stake reduction in Q3 2026.
Small-cap exposure offers diversification but faces near-term pressure from tightening financial conditions. The ETF's broad Russell 2000 composition includes unprofitable companies, creating performance drag. Upside potential exists if economic conditions improve, but current momentum favors large-caps amid rising interest rates and energy price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
